Gage et al reported the HEMORR2HAGES score to help to identify a patient with atrial fibrillation who is at risk for excessive bleeding during antithrombotic therapy. Recognition of bleeding risk can be helpful in guiding patient management. The authors are from Washington University and Yale-New Haven Health.
Parameters:
(1) hepatic or renal disease (H)
(2) ethanol abuse (E)
(3) malignancy (M)
(4) older age (O)
(5) reduced platelet count or function (R)
(6) repeat hemorrhage or prior bleed or rebleeding risk (R2)
(7) hypertension (H) if uncontrolled
(8) anemia (A)
(9) genetic factors (G) such as CYP2C9 single nucleotide polymorphism
(10) excessive fall risk (E)
(11) stroke (S)
Parameter |
Finding |
Points |
---|---|---|
hepatic or renal disease |
absent |
0 |
|
present |
1 |
ethanol abuse |
absent |
0 |
|
present |
1 |
malignancy |
absent |
0 |
|
present |
1 |
older age |
age <= 75 years) |
0 |
|
age > 75 years |
1 |
reduced platelet count or function |
absent |
0 |
|
present |
1 |
prior bleed |
absent |
0 |
|
present |
2 |
uncontrolled hypertension |
absent |
0 |
|
present |
1 |
anemia |
absent |
0 |
|
present |
1 |
genetic factors |
absent |
0 |
|
present |
1 |
excessive fall risk |
absent |
0 |
|
present |
1 |
stroke |
absent |
0 |
|
present |
1 |
where:
• Therapy with antiplatelet drugs would be associated with reduced platelet function.
total score =
= SUM(points for all 11 parameters)
Interpretation:
• minimum score: 0
• maximum score 12
• The higher the score the greater the risk of hemorrhage.
Total Score |
Rate of Bleeding per 100 Patient Years of Warfarin |
0 |
1.9 |
1 |
2.5 |
2 |
3 |
3 |
8.4 |
4 |
10.4 |
>= 5 |
12.3 |
Purpose: To identify an older adult receiving antithrombotic therapy for atrial fibrillation who is at increased risk for bleeding using HEMORR2HAGES.
Specialty: Hematology Oncology, Clinical Laboratory, Pharmacology, clinical
Objective: risk factors, severity, prognosis, stage, complications, adverse effects, complication detection
ICD-10: D69, I48,